CYTK - Cytokinetics Charts, Trade Ideas, Earnings, Ratings

TRENDING : Top 50 TRCH (0%) SPY (0%) OCGN (0%) MOXC (0%) MGNI (0%) GSAT (0%) GRWG (0%) GOED (0%) GME (0%) FURY (0%) ETSY (0%) ENG (0%) CWH (0%) CRSR (0%) CPE (0%) CELH (0%) BZUN (0%) BFLY (0%) BBIG (0%) BA (-0.62%) AVXL (-5.33%) AU (0%) AMPUSD (%) AMC (0%) ABNB (0%)

CYTK - Cytokinetics

$22.15 0[0%]

15 mins delayed data

People also watch : ARQL | EIGR | LGND | ARRY | GTXI | TRVN

+Watchlist

5 StockHoot Traders following this.
Analyst Ratings | Earnings

Previous Close	$22.15	Open
Volume		Market Cap	1.562B
Yield		Last Dividend

Day

52 Week

Cytokinetics completes enrollment in lat...	06/15/21
No summary available.

Cytokinetics to Participate in Upcoming ...	06/02/21
SOUTH SAN FRANCISCO, Calif., June 02, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, Presiden...

Cytokinetics to Participate in Upcoming ...	06/01/21
Cytokinetics, Incorporated announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to participate in three virtual fireside...

Heart Failure Treatment Market SWOT Anal...	05/31/21
Edison, NJ -- ( SBWIRE ) -- 05/31/2021 -- The Latest survey report on Global Heart Failure Treatment Market sheds lights on changing dynamics of each ...

Cytokinetics and ALS association renew p...	05/19/21
No summary available.

Cytokinetics and The ALS Association Ren...	05/19/21
SOUTH SAN FRANCISCO, Calif. and WASHINGTON, May 19, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) and The ALS Association today a...

Cytokinetics (CYTK) Gets a Buy Rating fr...	05/18/21
Raymond James analyst Dane Leone maintained a Buy rating on Cytokinetics (CYTK) yesterday. The companys shares closed last Monday at $25. The post Cyt...

Needham Gives a Buy Rating to Cytokineti...	05/18/21
Needham analyst Chad Messer assigned a Buy rating to Cytokinetics (CYTK) today and set a price target of $33.00. The post Needham Gives a Buy Rating t...

Cytokinetics Post-Hoc Data Suggests Omec...	05/17/21
Cytokinetics Incorporated (NASDAQ: CYTK) announced secondary data analysis from the GALACTIC-HF trial evaluating omecamtiv mecarbil in patients with h...

Days ahead of Amgen split, Cytokinetics ...	05/17/21
While Cytokinetics heart drug technically met its primary endpoint back in November, it missed a key secondary endpoint reduction in cardiovascular d...

Cytokinetics Announces Secondary Analysi...	05/16/21
Analysis Shows Treatment Effect of Omecamtiv Mecarbil Increased Progressively as Baseline Ejection Fraction Decreased

ACC 2021: With Amgen out of the picture,...	05/16/21
ACC 2021: With Amgen out of the picture, Cytokinetics imagines supporting role for omecamtiv in heart failure aarmstrong Sun, 05/16/2021 - 19:11

$5.68 Million in Sales Expected for Cyto...	05/12/21
Analysts predict that Cytokinetics, Incorporated (NASDAQ:CYTK) will announce sales of $5.68 million for the current quarter, according to Zacks. Three...

Cytokinetics, Incorporated (NASDAQ:CYTK)...	05/11/21
Cytokinetics, Incorporated (NASDAQ:CYTK) has been assigned a consensus recommendation of Buy from the twelve ratings firms that are covering the stock...

Cytokinetics stock price target raised t...	05/11/21
This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the ...

Analysts Offer Insights on Healthcare Co...	05/11/21
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Cytokinetics (CYTK), Revance Therapeutics (RVNC) and ...

Cytokinetics Incorporated Shares Close t...	03/12/21
Cytokinetics Incorporated shares closed today 12.4% higher than it did at the end of yesterday. The stock is currently up 9.8% year-to-date, up 113.7...

Cytokinetics Incorporated Shares Close t...	12/11/20
Cytokinetics Incorporated shares closed the week 13.9% higher than it did at the end of last week. The stock is currently up 87.4% year-to-date, up 1...

ANALYST RATINGS

3 analyst ratings (Last 3 months)

100.00 %

Strong Buy + Buy

Price Target (PT)

Strong Buy rating	04/19/21
Morgan Stanley maintains Overweight rating and raises Price Target from $24.00 to $35.00

EARNINGS

Date	04/12/2019 (AMC)	Est. (EPS/Rev.)	$1.37
Actual (EPS/Rev.)	$2.5B	EPS (TTM)	$???

TRADERS TRACKING $CYTK

Service Name	Trader	% Success
FEAT. ANDRE 3000	JOHN KROLIKOWSKI JR	84.00 %	Follow
Tech Trades	Tech Trades	79.00 %	Follow
FEAT. MIGUEL	JOHN KROLIKOWSKI JR	77.00 %	Follow
Arbitrage Trade Analytics	Royce Wells	72.00 %	Subscribe
FEAT. LIL WAYNE	JOHN KROLIKOWSKI JR	42.00 %	Follow

SHOW ALL TRADERS

About Us

Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.

Product Types

Strategies

Follow Us

Secure Payments

We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.